

## **Genetic study from North India -Two Cases of Trisomy 21**

### **Abstract:**

Down's Syndrome is a chromosomal abnormality with a gain of a third copy of chromosome 21, characterized by craniofacial abnormalities, intellectual developmental delay and growth retardation. In the present study, one-day-old neonate and a patient with an aborted fetus were presented to rule out genetic aberrations via CMA screening. DNA was extracted using from the case samples and evaluated by CMA Affymetrix platform. Chromosomal abnormalities in the fetus such as trisomy emerges due to several factors including maternal age, genetic mutational events, non-disjunction of chromosomes and epigenetic changes. CMA is an effective tool for predicting and diagnosing chromosomal abnormalities which needs to be promoted in India for healthy pregnancy outcomes. We report two cases of confirmed post-natal Trisomy 21.

**Keywords: Chromosomal Microarray, Down's Syndrome, Maternal Age, Chromosome 21, Diagnosis, Trisomy**

### **Introduction**

Chromosomal abnormalities in the fetus such as trisomy are very common due to several factors including maternal age, anatomy, and environment. Down's Syndrome (DS) is a chromosomal abnormality characterized by mental retardation and reduced growth. It is a genetically abnormal condition/disorder with a full or partial gain of a third copy of chromosome 21 (chr.21). Advanced maternal age remains one of the major risk factors for the nondisjunction of chromosomes leading to the development of chromosomal aneuploidy. Cytogenetic techniques, chromosomal microarray assay (CMA), and next-generation sequencing have been in use efficiently for the diagnosis of chromosomal aneuploidies including deletions, and duplications. Trisomy 21 is a common chromosomal anomaly and about 80% of cases result in miscarriage (1,2). T21 is the most common autosomal disorder which occurs due to the non-disjunction of chr.21 during the first or second meiotic division

of maternal or paternal gametogenesis (3,4). The disease was described by John Langdon Down first of all, as “Mongolian Idiocy” in 1866 (5). However, the term “Mongolism” was justifiably criticized for its racial implications (5). Therefore, it is also known as T21 or Down Syndrome (DS). According to a study, 95% of DS cases are due to T21 (6). The remaining 5% comprise the translocation and mosaic types of DS.

Three types of changes may occur at chromosomal level causing DS: i) *Complete Trisomy* - the presence of 3 chromosomes formed during fertilization in all the cells of an individual, ii) *Mosaic Trisomy* (less than 5% of DS cases) - some of the cells in the body have extra chromosome 21 and not all and iii) *Translocation Trisomy* - when a chr.21 is attached to another chr e.g., chr.21(21;21), chr14, 13, 15, or 22. The annual birth rate of DS babies is around 40,000 accounting for 1.4/1000 live birth in India. Recurrent pregnancy loss is a challenging reproductive health concern that impacts a significant percentage of couples, approximately ranging from 2% to 5%, cytogenetic abnormalities being one of the leading causes in addition to various other epigenetic factors (7).

CMA is in practice since 2010 in clinical diagnosis and decision-making and is a gold standard technique performed either using an array of comparative genomic hybridization (aCGH) or SNP array to detect copy number variations (CNVs) (8). A CNV is defined as a segment of DNA at least 1 kb in size that differs in copy number compared to the reference genome (10). In repro-genetic screening tests, it is on par with cytogenetics tests such as karyotyping and FISH and it includes sub-microscopic deletion or duplication of specific loci on the chromosome of a specific gene linked with the clinical condition (8). Identification sub-microscopic imbalances or CNVs which are not detected in other cytogenetic tests. It is a reliable technique to identify chromosomal abnormalities and imbalances in miscarried foetuses and stillbirths (9,10).

We report two cases of confirmed post-natal T21 in a day-old preterm neonate and another in an aborted fetus (Table 1). Genomic DNA was extracted from blood lymphocytes (blood samples collected in EDTA vacutainers) and the product of conception (POC) using Qiagen DNA blood mini kit. After checking the DNA concentration using nanodrop, and gel electrophoresis subjected to chromosomal microarray. The 250 ng of genomic DNA were fragmented, amplified, and hybridized to the array according to the manufacturer`s guidelines.

The CytoScan™ HD Array enables the detection of high-resolution copy numbers across the genome as well as providing allelic imbalance information from single nucleotide polymorphisms (SNPs). The results were analysed with the Chromosome Analysis Suite (ChAS, Affymetrix) and interpreted according to the ACMG guidelines.

The detected variants are classified as follows:

- i) Pathogenic – CNV with sufficient disease related evidence to be classified as pathogenic
- ii) Likely pathogenic – CNV with strong disease related evidence in favour of pathogenicity
- iii) Benign – CNV with sufficient non-disease related evidence to classify as benign
- iv) Likely benign – CNV with non-disease related strong evidence against pathogenicity
- v) Uncertain significance – CNV with limiting and/or conflicting evidence regarding pathogenicity

## Results

Pathogenic copy number variants have been detected by Chromosomal Microarray Analysis in both the cases.

### Case I:

Two pathogenic CNVs have been found to encompass chr.21: loci q11.2-22.3 & q22.3-q22.3, together, measuring nearly 3.3Mb (Table 2 & Figure 2). The OMIM genes: SOD1 (147450), TIAM1 (600687), SYNJ1 (604297), MRAP (609196), DONSON (611428), DSCR4 (604829), CFAP410 (603191), TRAPPC10 (602103), ADARB1(601218), and LSS (600909) are responsible for neurodevelopmental disorder, microcephaly, short stature, and speech delay, developmental and epileptic encephalopathy, limb abnormalities, intellectual disability, dysmorphic features, hypotonia and short stature characteristic of T21.

**Table 1: Trisomy 21 clinical case details**

Case	Sample	Status	History	Clinical Indications
I	Blood	One day old Preterm neonate (35weeks)	a) Advanced maternal age (35yrs. 4mo.) b) Antenatal scan diagnosis of Ascitis with thickened pulmonary valve c) Severe pulmonary stenosis with right dilated atrium & ventricles d) Dysfunctional right ventricle with hydrops	2D echo showed dilated right ventricle, hypotonia, dysmorphic facial features with upward slanting eyelids, serpentine tongue, short single palmer crease, short neck with congenital heart disease.

II	POC	Aborted fetus	a) Age (30 yrs.) b) Previous history of miscarriage	Ultrasound report showed a single gestational sac with a weak decidual reaction, cardiac activity was absent.
----	-----	---------------	--	---

**Table 2: T21 CMA analysis using ChAS suite – Case I**

**Table 3: T21 CMA analysis using ChAS suite – CaseII**

Chr.	Cyto band	Size (kbp)	Type	CN State	OMIM Genes	Microarray Nomenclature	Interpretation
21	q11.2-q22.3	33090.915	Gain	3.0	167	arr[GRCh37] 21q11.2q22.3(15006458_48097372)x3	Pathogenic

Chr.	Cyto band	Size (kbp)	Type	CN State	OMIM Genes	Microarray Nomenclature	Interpretation
21	q11.2-q22.3	29962	Gain	3.0	129	arr[GRCh37] 21q11.2q22.3(15006458_44968648)x3	Pathogenic
21	q22.3-q22.3	3123	Gain	3.0	39	arr[GRCh37] 21q22.3(44974018_48097372)x3	Pathogenic

### Case II:

A pathogenic gain of over 3.3Mb was found on chr. 21q11.2- 22.3 (Table 3 & Figure 3) and has been reported in the OMIM database to be associated with Down's syndrome. It comprises of genes, TRAPPC10(602103), SYNJ1(604297), SIK1(605705), ADARB1(601218), DONSON(611428), PCNT(605925), TIAM1(600687), and WDR4(605924) related to neurodevelopmental disorder, intellectual disability, dysmorphic features, hypotonia and short stature. All these phenotypic features are T21 specific to the Down's Syndrome (11).

### Discussion:

Miscarriage is a multifactorial clinical condition and may occur due to Trisomies, chromosomal abnormalities or unfavourable epigenetic changes. Women with a previous

history of miscarriage due to trisomies have been reported to be at higher risk of further conception with trisomies/aneuploidies, which are the result of nondisjunction during meiosis (12). DS remains the most common chromosomal condition, occurring in 1 of every 733 births. According to estimates only 80% of T21 pregnancies end in a miscarriage or intrauterine fetal demise, and only 20% may progress to term delivery (13). Down syndrome survivors have to face a number of clinical conditions ranging from intellectual disabilities, craniofacial features, congenital heart defects and leukemia. We report two cases of confirmed T21 with gain on chromosome 21.

Advanced maternal age remains one of the major risk factors of nondisjunction (14), However, the biological mechanisms of this phenomenon are still not clear. The majority of cytogenetic studies indicated that the origin of the extra chromosome was maternal in about 80% of the informative cases and paternal in about 20% (15,16). Nondisjunction in maternal meiosis I has been reported to be associated with reduced recombination between the non-disjoined chromosomes 21 (17,18), suggesting an important role for pairing/recombination failure or reduced recombination in the etiology of T21. Several clinical studies in India and other countries reported infants born with Trisomies (19). Aging affects female fertility resulting in reduced oocyte quality and implantation rates, and increased spontaneous abortions. The occurrence of foetal miscarriage gradually increases from 5.3% in women aged  $\leq 30$  years to 7.6% in women aged 31–34 years, 12.8% in women aged 35–39 years and 22.2% in women aged  $\geq 40$  years. Also, the incidence of pregnancy losses affected by aneuploidy is lower in women aged  $< 40$  years (65%) compared with women aged  $> 40$  years (82%). Trisomy cases occur at a low frequency of  $\sim 2\%$  among women under the age of 25 years after which the frequency increases to over 40% at ages  $> 40$  years (20-24).


Essentially there is an increased risk of errors during meiosis in chromosome segregation. In oocyte development, these errors can occur at any stage during: (i) primordial germ cell mitotic proliferation for oogonia generation (ii) oocyte meiotic division and (iii) early embryo mitosis after fertilization. Meiosis involves two cell divisions (MI and MII) that produce haploid gametes. During prophase I, which occurs in the fetal ovary, events such as chromosome pairing, synapsis, and crossing over (recombination) facilitate the exchange of genetic material between maternal and paternal chromosomes. Crossover creates chiasmata, physical links between homologous chromosomes, ensuring their proper segregation during metaphase I. At birth, oocytes arrest at the diplotene or dictyotene stage of prophase I and remain arrested until ovulation, surrounded by follicular cells in the primordial follicle. In each menstrual cycle, luteinizing hormone triggers oocytes to resume meiosis I. Homologous

chromosomes segregate during MI, and the oocyte enters meiosis II, where sister chromatids separate. Oocytes remain arrested at metaphase II until fertilization. Different chromosome segregation patterns contribute to oocyte aneuploidy (20-26). Nondisjunction (NDJ) occurs when the sister chromatids fail to separate properly. Premature sister chromatid separation (PSCS) and reverse segregation (RS) are other patterns observed. PSCS involves early separation of one homolog's sister chromatids, while RS results in sister chromatids of both homologs separating at meiosis I. These patterns can lead to aneuploidy, but some oocytes still have the correct number of chromosomes at the end of meiosis. Maternal age plays a significant role in oocyte aneuploidy, with increased risk in older women and miscarriages. Several mechanisms have been proposed to explain the higher incidence of oocyte aneuploidy in older females.

**Figure 1: Trisomy due to non-disjunction of chromosomes during Meiosis I & II**

These include meiotic recombination failure, deterioration of chromosome cohesion, defects in the spindle assembly checkpoint (SAC) mechanism, alterations in histone and tubulin modifications, and mitochondrial dysfunction leading to oocyte aneuploidy (25-30).

SNP-based arrays in CMA are being used to detect aneuploidy, polyploidy, whole-genome



homozygosity, and segmental genomic imbalances, with high sensitivity and reduced false-negative results with better yield than karyotyping and FISH [18]. CNVs detected in both the samples in our study were pathogenic and pathologically significant with respect to T21.

In case I, the reason for trisomy, might be advanced maternal age which is the most common factor influencing the disjunction of chromosomes leading to T21. However, In the second case, T21 is suspected to be the pre-eminent cause of fetal demise. The patient also had a clinical history of recurrent miscarriages. The couple was not made aware of genetic testing or prenatal screening with a lack of proper follow-up until the subsequent miscarriage.



Figure 2: ChAS suite karyoview and IGV profile showing T21 in case I (neonate) (47, XY,+21), gain ▲




Figure 3: ChAS suite karyoview and IGV profile showing T21 in case II (46, XX,+21), gain ▲

Various genes present on the q-arm of chr.21 are implicated in DS and related phenotypic features. The *Superoxide Dismutase 1* (*SOD1*:147450) gene encodes superoxide dismutase, an enzyme associated with amyotrophic lateral sclerosis (ALS). In T21 (DS), elevated levels of this enzyme have been reported. *T-Cell Lymphoma Invasion and Metastasis 1* (*TIAMI*:600687) is linked to a neurodevelopmental disorder characterized by language delay and seizures. Another gene, *Synaptojanin 1* (*SYNJI*:604297) encodes synaptojanin-1, which is involved in synaptic vesicle dynamics. Changes in its activity can lead to developmental and epileptic encephalopathy and Parkinson's disease, while altered enzyme activity can be associated with DS. *Melanocortin 2 Receptor Accessory Protein* (*MRAP*:609196) is associated with glucocorticoid deficiency 2, a disorder resulting from resistance to adrenocorticotropin in the adrenal cortex. Affected individuals have cortisol deficiency and are at risk of hypoglycaemia or severe infections if left untreated but not directly related to T21. Microcephaly, short stature, and limb abnormalities may be caused by mutations in *Downstream Neighbor of SON* (*DONSON*:611428). The critical locus of *DSCR4*: 604829, is part of the Down syndrome critical region (*DSCR*) on chr. 21 and spans a 1.6-Mb region on chromosome 21q22.2, between the DNA marker LA68 and ERG (Dunn et al., 2006). The *Cilia- and Flagella-Associated Protein 410* (*CFAP410*:603191) is involved in ciliogenesis and DNA damage repair, but its relationship to trisomy 21 or Down syndrome is unclear. The *Trafficking Protein Particle Complex, Subunit 10* (*TRAPPC10*:602103) is associated with neurodevelopmental disorder characterized by microcephaly, short stature, and speech delay. Mutations in the *Adenosine Deaminase, RNA-Specific, B1* (*ADARBI*:601218) mutations are associated with a neurodevelopmental disorder characterized by hypotonia, microcephaly, and seizures. Variations in *Lanosterol Synthase* (*LSS*:600909) can lead to a syndrome involving alopecia (hair loss), intellectual disability, and cataracts. While LSS is not directly associated with trisomy 21, it plays a role in cholesterol biosynthesis, which may have broader implications in genetic conditions. In human foetal neurons *Salt-Inducible Kinase 1* (*SIK1*:605925) mutations are related to developmental and epileptic encephalopathy and abnormal neuronal morphology whereas, changes in *Pericentrin* (*PCNT*:605925) is associated with microcephalic osteodysplastic primordial dwarfism, type II. Another important gene *WD Repeat-Containing Protein 4* (*WDR4*:605924) plays a role in tRNA modification, which is important for protein synthesis and mutations may lead to microcephaly, growth deficiency, seizures, and brain malformations.

In both the cases, unfortunately, the couple belonged to a remote area and were unaware of critical screening methods like CMA for ruling out chromosomal anomalies after anomalous

ultrasonography (USG) findings. These methodologies are much more prevalent in the urban areas to rule out chromosomal birth defects to be managed throughout life as. The couples were genetically counselled in both the cases and are under the follow up. The clinical interventions for 'Case I' are getting reviewed to devise a management plan for the Down's Syndrome affected neonate.

There are several challenges In India, regarding the use of Chromosomal microarray (CMA) as a diagnostic tool for detecting abnormalities in fetuses. The primary challenge being the limited availability and accessibility of such facilities across the country. Many parts of the country, especially the transitioning rural areas, and remote locations lack the necessary infrastructure and expertise to deploy CMA effectively restricting it to the developed cities.

Another roadblock is the affordability, as high costing makes it inaccessible the lower socioeconomic diaspora. Which in turn limits their access to accurate and comprehensive genetic testing as well as limiting the doctors to recommend it.

Moreover, the complicated paradigm of ethical considerations and awareness towards adoption of CMA in India is far from easy to navigate. Many individuals are unaware of the benefits and capabilities of this latest diagnostic advancement, leading to underutilization and delayed diagnosis. To overcome these difficulties, efforts are needed to improve the accessibility of CMA testing in an economic manner. Moreover, awareness campaigns and educational health camps across the country need to be undertaken to enhance the public comprehension for promoting its utilization. Crucial focus should be placed on encouraging safe pregnancy management and ethical practices in prenatal care in accordance to the regional regulations safeguard at the same time.

**Conclusion:** CMA is a reliable technique and has become the 1<sup>st</sup> tier diagnostic tool to detect chromosomal aneuploidies in prenatal as well as in post-natal samples especially in case of evident phenotypic neurological deficits and growth delays such as in Down's Syndrome. The use of CMA to understand and diagnose sudden/recurrent foetal demise or missed abortion helps at the genomic level in terms of appropriate decision-making and clinical management for further planning of a healthy pregnancy. Essentially, prenatal diagnosis should be made mandatory for females having advanced maternal age and in case of a miscarriage to rule out any major genetic anomaly. It can help plan for a better diagnostic intervention like Carrier sequencing, Exome sequencing for better planning of a future pregnancy to lessen the medical as well as emotional burden on families. The government, medical and diagnostic institutions need to come together and devise effective ethical strategies for healthy pregnancy and maternal welfare for healthier children.

## References:

1. Pennington BF, Moon J, Edgin J, Stedron J, Nadel L. The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. *Child Dev.* 2003; 74: 75–93.
2. Antonarakis SE, Lyle R, Dermitzakis ET, Reymond A, Deutsch S. Chromosome 21 and down syndrome: from genomics to pathophysiology. *Nat Rev Genet.* 2004; 5: 725–38.
3. De Grouchy J, Tourleau C. T21, In: *Clinical Atlas of Human Chromosomes*, (Ed. V.A. McKusick), New York, Wiley Medical Publications 1984; 338-45.
4. Hassold TA, Sherman S DS. Genetic recombination and origin of the extra chromosome 21. *Clinical Genetics* 2000;57: 95-100.
5. Balwan WK, Raina TR, Kumar P, Sharma S, Raina S, Gupta S. Down's Syndrome: A chromosome study of 118 cases from Jammu and Kashmir, India. *IJEM* 2008;12(6 & 7):5-8
6. Mikkelsen M. The effect of maternal age on the incidence of DS. *Human Genetics* 1972;16:141-146.
7. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, Church DM, Crolla JA, Eichler EE, Epstein CJ, Faucett WA, Feuk L, Friedman JM, Hamosh A, Jackson L, Kaminsky EB, Kok K, Krantz ID, Kuhn RM, Lee C, Ostell JM, Rosenberg C, Scherer SW, Spinner NB, Stavropoulos DJ, Tepperberg JH, Thorland EC, Vermeesch JR, Waggoner DJ, Watson MS, Martin CL, Ledbetter DH. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. *Am J Hum Genet.* 2010; 14;86(5):749-64.
8. Levy B, Wapner R. Prenatal Diagnosis by Chromosomal Microarray Analysis. *Fertility and Sterility* 2018;109(2);201-12.
9. Zhu, X., Li, J., Zhu, Y. et al. Application of chromosomal microarray analysis in products of miscarriage. *Mol Cytogenet* 2018;11: 44.
10. Kearney HM, Thorland EC, Brown KK, Quintero-Rivera F, South ST; Working Group of the American College of Medical Genetics Laboratory Quality Assurance Committee. American College of Medical Genetics standards and guidelines for

interpretation and reporting of postnatal constitutional copy number variants. *Genet Med.* 2011;13:680-85.

11. Online Mendelian Inheritance in Man, OMIM®. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD), {date}. World Wide Web URL: <https://omim.org/>
12. Warburton D, Dallaire L, Thangavelu M, Ross L, Levin B, Kline J. Trisomy recurrence: a reconsideration based on north American data. *Am J Hum Genet.* 2004;75:376–85.
13. Antonarakis SE, Lyle R, Dermitzakis ET, Reymond A, Deutsch S. Chromosome 21 and down syndrome: from genomics to pathophysiology. *Nat Rev Genet.* 2004; 5: 725–38.
14. Penrose LS, The relative effect of paternal and maternal age in Mongolism. *J Genet* 1933; 27: 219 -24.
15. Juberg RC, Mowrey PN. Origin of nondisjunction in T21 syndrome: all studies compiled, parental age analysis, and international comparisons. *Am J med Genet* 1983;16:111–16 .
16. Hassold TJ, Jacobs PA: Trisomy in man. *A Rev Genet* 18:69–97 (1984).
17. Warren AC, Chakravarti A, Wong C, Slaugenhaupt SA, Halloran SL, Watkins PC, Metaxotou C, Antonarakis SE: Evidence for reduced recombination on the nondisjoined chromosomes 21 in Down syndrome. *Science* 1987; 237:652–54.
18. El Hachem H, Crepaux V, May-Panloup P, Descamps P, Legendre G, Bouet PE. Recurrent pregnancy loss: current perspectives. *Int J Womens Health.* 2017;9:331-45.
19. Manikandan K, Seshadri S. Down Syndrome Screening in India: Are We There Yet? *The Journal of Obstetrics and Gynecology of India* 2017 ;67(6):393–99
20. El Yakoubi W, Wassmann K. Meiotic Divisions: No Place for Gender Equality. *Adv Exp Med Biol.* 2017;1002:1-17.
21. Duro E, Marston AL. From equator to pole: splitting chromosomes in mitosis and meiosis. *Genes Dev.* 2015 (15);29(2):109-22.
22. Clift D, Schuh M. Restarting life: fertilization and the transition from meiosis to mitosis. *Nat Rev Mol Cell Biol.* 2013 Sep;14(9):549-62
23. Buccione R, Schroeder AC, Eppig JJ. Interactions between somatic cells and germ cells throughout mammalian oogenesis. *Biol Reprod.* 1990;43(4):543-7.
24. Watanabe Y. Geometry and force behind kinetochore orientation: lessons from meiosis. *Nat Rev Mol Cell Biol.* 2012(16);13(6):370-82.

25. Lee J, Kitajima TS, Tanno Y, Yoshida K, Morita T, Miyano T, Miyake M, Watanabe Y. Unified mode of centromeric protection by shugoshin in mammalian oocytes and somatic cells. *Nat Cell Biol.* 2008;10(1):42-52.
26. Webster A, Schuh M. Mechanisms of Aneuploidy in Human Eggs. *Trends Cell Biol.* 2017;27(1):55-68.
27. Gabriel AS, Thornhill AR, Ottolini CS, Gordon A, Brown AP, Taylor J, Bennett K, Handyside A, Griffin DK. Array comparative genomic hybridisation on first polar bodies suggests that non-disjunction is not the predominant mechanism leading to aneuploidy in humans. *J Med Genet.* 2011;48(7):433-7.
28. Handyside AH. Molecular origin of female meiotic aneuploidies. *Biochim Biophys Acta.* 2012;1822(12):1913-20.
29. Ottolini CS, Newnham L, Capalbo A, Natesan SA, Joshi HA, Cimadomo D, Griffin DK, Sage K, Summers MC, Thornhill AR, Housworth E, Herbert AD, Rienzi L, Ubaldi FM, Handyside AH, Hoffmann ER. Genome-wide maps of recombination and chromosome segregation in human oocytes and embryos show selection for maternal recombination rates. *Nat Genet.* 2015;47(7):727-35.
30. Gruhn JR, Zielinska AP, Shukla V, Blanshard R, Capalbo A, Cimadomo D, Nikiforov D, Chan AC, Newnham LJ, Vogel I, Scarica C, Krapchev M, Taylor D, Kristensen SG, Cheng J, Ernst E, Bjørn AB, Colmorn LB, Blayney M, Elder K, Liss J, Hartshorne G, Grøndahl ML, Rienzi L, Ubaldi F, McCoy R, Lukaszuk K, Andersen CY, Schuh M, Hoffmann ER. Chromosome errors in human eggs shape natural fertility over reproductive life span. *Science.* 2019 (27);365.